X0306 4 2017-11-21 0 0001604950 scPharmaceuticals Inc. SCPH 0001197089 SUN PHARMACEUTICAL INDUSTRIES LTD SUN HOUSE, 201 B/1, WESTERN EXPRESS HIGHWAY, GOREGAON (E) MUMBAI MAHARASHTRA K7 400063 INDIA 0 0 1 0 0001249644 SHANGHVI DILIP S SUN HOUSE, 201 B/1, WESTERN EXPRESS HIGHWAY, GOREGAON (E) MUMBAI MAHARASHTRA K7 400063 INDIA 0 0 1 0 0001717322 Sun Pharma (Netherlands) B.V. POLARISAVENUE 87 HOOFDDORP P7 2132 JH NETHERLANDS 0 0 1 0 0001721949 Sun Pharmaceutical Industries, Inc. 270 PROSPECT PLAINS ROAD CRANBURY NJ 08512 0 0 1 0 Common Stock 2017-11-21 4 C 0 1810536 A 1810536 I By Sun Pharmaceutical Industries, Inc. Common Stock 2017-11-21 4 P 0 357143 14.00 A 357143 I By Sun Pharma (Netherlands) B.V. Series B Preferred Stock 2017-11-21 4 C 0 13000000 0.00 D Common Stock 1810536 0 I By Sun Pharmaceutical Industries, Inc. Represents the total number of shares of Common Stock received by Sun Pharmaceutical Industries, Inc. upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. Sun Pharmaceutical Industries Limited ("Sun Pharma") directly and indirectly owns all shares of Sun Pharmaceutical Industries, Inc., which is the registered owner of the securities. Sun Pharma may be deemed to beneficially own all of the shares of the Issuer held by Sun Pharmaceutical Industries, Inc. Dilip S. Shanghvi is the controlling shareholder of Sun Pharma. Sun Pharma and Mr. Shanghvi disclaim beneficial ownership of the reported shares except to the extent of their respective pecuniary interests therein. Sun Pharma is the sole shareholder of Sun Pharma (Netherlands) B.V., which is the registered owner of the securities. Sun Pharma may be deemed to beneficially own all of the shares of the Issuer held by Sun Pharma (Netherlands) B.V. Dilip S. Shanghvi is the controlling shareholder of Sun Pharma. Sun Pharma and Mr. Shanghvi disclaim beneficial ownership of the reported shares except to the extent of their respective pecuniary interests therein. All series of the Issuer's Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017. The Series B Preferred Stock had no expiration date. Exhibit 24 - Power of Attorney /s/ Dilip S. Shanghvi 2017-11-24 /s/ Jeremy Barr, Attorney-in-Fact (on behalf of Sun Pharmaceutical Industries Limited) 2017-11-24 /s/ Jeremy Barr, Attorney-in-Fact (on behalf of Sun Pharmaceutical Industries, Inc.) 2017-11-24 /s/ Jeremy Barr, Attorney-in-Fact (on behalf of Sun Pharma (Netherlands) B.V.) 2017-11-24